Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047242 · ClinicalTrials.gov registry record · Phase 1
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00047242 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 30 participants.
The verdict
NCT00047242, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with irinotecan in treating patients who have advanced solid tumors.
Interventions
- DRUG irinotecan hydrochloride
- DRUG 7-hydroxystaurosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047242
The ClinicalTrials.gov registry entry for NCT00047242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00047242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047242 about?
NCT00047242 is a clinical study titled "UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors". RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase I t...
What is the current status of trial NCT00047242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-08.
What interventions are being tested in trial NCT00047242?
The interventions under investigation include: irinotecan hydrochloride (DRUG), 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00047242?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.